Internal Medicine, Medical Oncology · Baltimore, MD
NPI
1578507976
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
600 N Wolfe St
Baltimore, MD, 21287
Phone (410) 955-8964
Groups this clinician bills Medicare through
Medicare paid, 2024
$61K
629 services
Medicare patients, 2024
149
Average age 72
Drug cost, 2024
$5.1M
805 prescriptions
Company payments, 2025
$59K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark Levis was code 99215 (office e&m - established), 290 times for 64 patients. In total Mark Levis billed 629 services in 16 codes, and Medicare paid $61K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 290 | 64 | $110.79 | $32K |
| 99233 Hospital E&M - Subsequent | Facility | 216 | 46 | $91.80 | $20K |
| 85097 Test - Miscellaneous | Facility | 32 | 32 | $36.55 | $1,170 |
| 99239 Hospital Discharge Management | Facility | 27 | 27 | $89.57 | $2,418 |
| 99223 Hospital E&M - Initial | Facility | 20 | 20 | $126.99 | $2,540 |
| 99205 Office E&M - New | Facility | 11 | 11 | $149.17 | $1,641 |
By year: 2022 $54K for 594 services; 2023 $58K for 577 services; 2024 $61K for 629 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark Levis prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 108 prescriptions and refills. In total Mark Levis wrote 805 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 108 | 199 | 31 | $6,067 |
| Xospata Gilteritinib Fumarate | 92 | 92 | 12 | $2.3M |
| Tibsovo Ivosidenib | 48 | 48 | Under 11 | $1.5M |
| Tramadol Hcl Generic | 39 | 39 | Under 11 | $310 |
| Venclexta Venetoclax | 31 | 35 | 12 | $177K |
| Idhifa Enasidenib Mesylate | 28 | 28 | Under 11 | $894K |
| Sprycel Dasatinib | 24 | 24 | Under 11 | $118K |
| Famotidine Generic | 24 | 24 | Under 11 | $237 |
| Pantoprazole Sodium Generic | 23 | 37 | Under 11 | $253 |
| Levothyroxine Sodium Generic | 21 | 25 | Under 11 | $79.41 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 20 | 20 | Under 11 | $170 |
| Furosemide Generic | 15 | 24 | Under 11 | $52.83 |
| Metoprolol Succinate Generic | 14 | 22 | Under 11 | $122 |
| Losartan Potassium Generic | 13 | 19 | Under 11 | $58.28 |
| Tamsulosin Hcl Generic | 13 | 27 | Under 11 | $222 |
Brand drugs: 266 claims; generic drugs: 539 claims; opioid claims: 58.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark Levis $59K ($59K in general payments such as food, travel and fees) from 8 companies. The largest payer was Astellas Pharma Inc with $16K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.